Soligenix Stocks Increase After Hitting Trial Goal
Soligenix’s cutaneous T-cell lymphoma treatment has just managed to hit the goal for a phase 3 trial which has driven shares in the nanocap biotech drug development company up almost 50% at points in premarket trading. The trial was designed to test SGX301 which is a synthetic form of hypericin; the drug was moved into …